Skip to main content
Shanghai Bao Pharmaceuticals Co., Ltd. logo

Shanghai Bao Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 2659 ISIN · CNE100007B92 HKEX Manufacturing
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2659

About Shanghai Bao Pharmaceuticals Co., Ltd.

https://www.baopharma.com

Shanghai Bao Pharmaceuticals Co., Ltd., established in 2019, is an innovative biotechnology company focused on the clinical development, industrialization, and commercialization of recombinant protein and antibody-based therapeutics. The company leverages synthetic biology technology and its proprietary subcutaneous (SC) drug delivery platform, Hysorptase, to advance novel biologic candidates. Shanghai Bao maintains a diverse clinical pipeline and has an approved product. Its portfolio includes finished dosage forms such as injectable solutions, lyophilized powder injections, and pre-filled syringes. A key product, Ricefidase (KJ103) Recombinant IgG Cleaving Enzyme, is developed to meet the clinical needs of patients suffering from acute and severe autoimmune diseases, organ transplant recipients, and individuals requiring gene therapy.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Shanghai Bao Pharmaceuticals Co., Ltd. It details movements in authorized/registered share capital, issued shares, treasury shares, and public float sufficiency confirmation for the month ended 30 April 2026. The document includes confirmations pursuant to HKEX listing rules and does not contain financial statements or management discussion. It is a regulatory compliance filing related to share capital and public float status, not a financial report or announcement of voting results. The document is a regulatory filing under HKEX rules, fitting the category of Regulatory Filings (RNS).
2026-05-06 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 26, 2026
AGM Information Classification · 100% confidence The document is a proxy form for the Annual General Meeting (AGM) of Shanghai Bao Pharmaceuticals Co., Ltd. It includes instructions for shareholders to appoint proxies to vote on various resolutions at the AGM, including approval of the 2025 Annual Report, election of directors, remuneration, and other corporate matters. The document is not the Annual Report itself, nor is it a report of voting results or a management report. It is a form used to facilitate voting at the AGM. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms.
2026-05-04 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a notice of the Annual General Meeting (AGM) for Shanghai Bao Pharmaceuticals Co., Ltd. It includes details about the date, location, agenda items such as approval of the 2025 Annual Report, election of directors, and other resolutions to be considered at the AGM. The document is a formal notice inviting shareholders to attend and vote at the AGM, not the actual annual report or financial statements themselves. It is over 10,000 characters, indicating it is a full notice rather than a brief announcement. The content aligns with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices and agendas. Therefore, the correct classification is AGM Information (AGM-R).
2026-05-04 English
CIRCULAR OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a circular issued by Shanghai Bao Pharmaceuticals Co., Ltd. regarding the upcoming Annual General Meeting (AGM) scheduled for May 26, 2026. It includes detailed information about the agenda items to be discussed and voted on at the AGM, such as approval of the 2025 Annual Report, 2025 Final Accounts Report and 2026 Financial Budget, work reports of the Board of Directors and Supervisors, profit distribution proposal, remuneration of directors, re-appointment of auditors, election of directors, general mandates to issue and repurchase shares, and proposed amendments to the Articles of Association. The document also contains a notice of the AGM and proxy form instructions. The text explicitly states it is a circular and notice for the AGM, providing information to shareholders to make informed decisions at the meeting. It does not contain the full annual report or financial statements themselves but refers to them as published elsewhere. Therefore, this document is best classified as AGM Information (AGM-R), as it is the presentation and materials shared for the Annual General Meeting, including the notice and explanatory circular.
2026-05-04 English
VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS AND PROPOSED SHAREHOLDING INCREASE BY CONTROLLING SHAREHOLDER AND INTENTION TO PROPOSE SHARE REPURCHASE MANDATE
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Shanghai Bao Pharmaceuticals regarding unusual price and trading volume movements, a proposed shareholding increase by a controlling shareholder, and an intention to propose a share repurchase mandate. It includes details about the controlling shareholder's intentions, compliance with listing rules, and a forthcoming special resolution at the upcoming AGM to approve the share repurchase mandate. The document does not contain financial statements or detailed financial data but is an announcement of corporate actions and intentions related to shareholding and share repurchase. This fits the category of Capital/Financing Update (CAP), as it relates to shareholding changes and share repurchase plans, which are financing activities. The document length (6722 characters) and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2026-05-03 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2025 Annual Report' for Shanghai Bao Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report, including company profile, chairman's statement, business highlights, financial highlights, management discussion and analysis, directors and senior management information, corporate governance report, environmental, social and governance report, independent auditor's report, consolidated financial statements, notes to financial statements, and financial summary. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content covers comprehensive financial and operational information for the fiscal year 2025, consistent with an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-27 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.